What are anti-amyloid antibodies, and how do they work?
They are not a cure. They are the first treatments that have been shown, in well-designed trials, to slow the underlying disease.
A plain-language explanation of the disease-modifying drug class that defines the current Alzheimer's treatment landscape.
What is ARIA, and why does it matter for treatment?
ARIA is the price of admission for amyloid clearance. Most cases are mild; a small minority are serious; all require monitoring.
Amyloid-related imaging abnormalities are the defining safety consideration of the anti-amyloid antibody class — and the reason MRI surveillance is built into treatment.
Why APOE4 matters in Alzheimer's disease and treatment
APOE4 status is no longer a research-only data point. It influences who is at higher risk, who tolerates treatment more easily, and what the conversation with a clinician looks like.
APOE4 is both the strongest common genetic risk factor for late-onset Alzheimer's and a meaningful modifier of treatment safety — which is why genotyping is now part of the workup.